Relugolix

Especificaciones

737789-87-6Número CAS

864-997-1Número CE

1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyureaNombre IUPAC

C29H27F2N7O5SFórmula química

623.6 g/molPeso molecular

Relugolix; 737789-87-6; TAK-385; Orgovyx; TAK 385; TAK385; P76B05O5V6; DTXSID40224167; MYFEMBREE COMPONENT RELUGOLIX; N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea; N-[4-[1-[(2,6-Difluorophenyl)methyl]-5-[(dimethylamino)methyl]-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-N'-methoxyurea; 1-(4-{1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1H,2H,3H,4H-thieno[2,3-d]pyrimidin-6-yl}phenyl)-3-methoxyurea; Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy-; relugolixum; 1-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1H,2H,3H,4H-thieno(2,3-d)pyrimidin-6-yl)phenyl)-3-methoxyurea; 1-(4-(1-((2,6-difluorophenyl)methyl)-5-(dimethylaminomethyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno(4,5-e)pyrimidin-6-yl)phenyl)-3-methoxyurea; 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-(dimethylaminomethyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[4,5-e]pyrimidin-6-yl]phenyl]-3-methoxyurea; Urea, N-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-N'-methoxy-; RefChem:57784; DTXCID40146658; 1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-3-methoxyurea; C29H27F2N7O5S; CHEMBL1800159; 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea; Relugolix [USAN:INN]; UNII-P76B05O5V6; Orgovyx (TN); MFCD25976856; Relugolix (Standard); RELUGOLIX [INN]; RELUGOLIX [JAN]; Relugolix(TAK-385); RELUGOLIX [USAN]; Relugolix(TAK-385)?; RELUGOLIX [WHO-DD]; Relugolix (JAN/USAN/INN); SCHEMBL778416; GTPL5586; orb1223060; orb1303979; orb3141153; RELUGOLIX [ORANGE BOOK]; SCHEMBL29386968; AOMXMOCNKJTRQP-UHFFFAOYSA-N; GLXC-10592; HMS5085J09; EX-A1083; TAK-385; RVT-601; BDBM50347982; EBC-17169; HY-16474R; s5808; AKOS027440398; Relugolix (TAK-385, RVT-601); CS-5917; DB11853; SB16721; AC-35863; BP-44043; BS-18032; HY-16474; NS00072569; D10888; EN300-19854622; F979301; Ryeqo (relugolix-estradiol-norethisterone acetate); Q21099000; 1-(4-{1-[(2,6-Difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl}phenyl)-3-methoxyurea; 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-thieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxy-urea; 1-{4-[1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea; N-(4-{1-[(2,6-Difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl}phenyl)-N'-methoxyurea; N-[4-[1-[(2,6-Difluorophenyl)methyl]-5-[(dimethylamino)methyl]-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-N'-methoxyurea; 1-[4-[1-[(2,6-Difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea; Orgovyx; RVT 601; TAK 385Sinónimos